Navigation Links
Northeastern researchers have discovered a new treatment to cure MRSA infection
Date:11/13/2013

Recent work from University Distinguished Professor of Biology Kim Lewis promises to overcome one of the leading public health threats of our time. In a groundbreaking study published Wednesday in the journal Nature, Lewis' team presents a novel approach to treat and eliminate methicillin resistant staphylococcus aureus, or MRSA, a potent bacterium whose resistance to antibiotics has kept it one step ahead of researchers. That is, until now.

The so-called "superbug" infects 1 million Americans each year. A major problem with MRSA is the development of deep-seated chronic infections such as osteomyelitis (bone infection), endocarditis (heart infection), or infections of implanted medical devices. Once established, these infections are often incurable, even when appropriate antibiotics are used.

Bacteria such as MRSA have evolved to actively resist certain antibiotics, a fact that has generated significant interest among the scientific and medical communities. But Lewis, Director of Northeastern's Antimicrobial Discovery Center, suspected that a different adaptive function of bacteria might be the true culprit in making these infections so devastating.

The new work represents the culmination of more than a decade of research on a specialized class of cells produced by all pathogens called persisters. According to Lewis, these cells evolved to survive. "Survival is their only function," he said. "They don't do anything else."

Lewis and his research team posited that if they could kill these expert survivors, perhaps they could cure chronic infectionseven those resistant to multiple antibiotics such as MRSA. Furthermore, said Brian Conlon, a postdoctoral researcher in Lewis' lab and first author on the paper, "if you can eradicate the persisters, there's less of a chance that resistance will develop at all."

Lewis, who was elected to the American Academy of Microbiology in 2011 for his scholarship in the field, has found that persisters achieve their singular goal by entering a dormant state that makes them impervious to traditional antibiotics. Since these drugs work by targeting active cellular functions, they are useless against dormant persisters, which aren't active at all. For this reason, persisters are critical to the success of chronic infections and biofilms, because as soon as a treatment runs its course, their reawakening allows for the infection to establish itself anew.

In the recent study, which also includes contributions from assistant professor Steve Leonard of the Department of Pharmacy Practice, Lewis' team found that a drug called ADEP effectively wakes up the dormant cells and then initiates a self-destruct mechanism. The approach completely eradicated MRSA cells in a variety of laboratory experiments and, importantly, in a mouse model of chronic MRSA infection.

Coupling ADEP with a traditional antibiotic, Conlon noted, allowed the team to completely destroy the bacterial population without leaving any survivors.

As with all other antibiotics, actively growing bacterial cells will likely develop resistance to ADEP. However, Lewis said, "cells that develop ADEP resistance become rather wimpy." That is, other traditional drugs such as rifampicin or linezolid work well against ADEP-resistant cells, providing a unique cocktail that not only kills persisters but also eliminates ADEP-resistant mutant bacteria.

Dr. Richard Novick of New York University's Langone Medical Center and a leader in the field said the research is a "brilliant outgrowth of Kim Lewis' pioneering work on bacterial persisters and represents a highly creative initiative in this era of diminishing antibiotic utility."

While ADEP targets MRSA, Lewis' team believes similar compounds will be useful for treating other infections as well as any other disease model that can only be overcome by eliminating a population of rogue cells, including cancerous tumors. They are pursuing several already.


'/>"/>

Contact: Kara Shemin
kara.shemin@neu.edu
617-373-2802
Northeastern University
Source:Eurekalert  

Related biology news :

1. Health-related quality of life in PD patients in northeastern Sicily, Italy
2. Oceanographer Sylvia Earle kicks off Northeasterns Sustaining Coastal Cities Conference
3. Sustaining Coastal Cities Conference at Northeastern University
4. Danish researchers predict risk of valvular heart disease
5. Using morphine after abdominal surgery may prolong pain, CU-Boulder researchers find
6. Wayne State researchers discover specific inhibitor for rheumatoid arthritis treatment
7. Protein illustrates muscle damage: McMaster researchers
8. NSF awards to UT Arlington researchers will fuel sustainable solutions
9. Researchers uncover origins of cattle farming in China
10. UT Southwestern researchers identify how body clock affects inflammation
11. Researchers suggest plan to address hypoxia in Gulf of Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Northeastern researchers have discovered a new treatment to cure MRSA infection
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... Irvine, ca (PRWEB) , ... October 12, 2017 ... ... for the Surgical Wound Market with the addition of its newest module, US ... the $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and ...
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
Breaking Biology Technology: